oxadiazoles has been researched along with Ocular-Hypertension* in 2 studies
2 other study(ies) available for oxadiazoles and Ocular-Hypertension
| Article | Year |
|---|---|
New furoxan derivatives for the treatment of ocular hypertension.
A small series of water-soluble NO-donor furoxans bearing a basic center at the 4-position, having a wide lipophilic-hydrophilic balance range, and endowed with different NO-release capacities, were synthesized and characterized. Selected members were studied for their IOP-lowering activity in the transient ocular hypertensive rabbit model at 1% dose. The most effective IOP-lowering products were compounds 3 and 7, whose activity 60min after administration was similar to that of Timolol. Notably, 7 was characterized by a long-lasting action. The IOP-lowering activity in this series of products appeared to be modulated by the lipophilic-hydrophilic balance rather than by the NO-donor capacity. Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Glaucoma; Intraocular Pressure; Nitric Oxide; Ocular Hypertension; Oxadiazoles; Rabbits; Solubility; Timolol | 2017 |
Nitric oxide donors: effects of S-nitrosoglutathione and 4-phenyl-3-furoxancarbonitrile on ocular blood flow and retinal function recovery.
It is known that NO is involved in the regulation of intraocular pressure (IOP) and retinal function recovery after ischemia. Thus, S-nitrosoglutathione (RVC-588) and 4-phenyl-3-furoxancarbonitrile (RVC-589) as NO donor and precursor, respectively, were studied in terms of their ability to increase b-wave recovery of electroretinogram (ERG) and ocular blood flow. It was found that RVC-588 increased b-wave amplitude markedly from 28% (control) to 67% (treated) and the blood flow significantly in the retina, choroid, and ciliary body. In the case of RVC-589, the b-wave recovery was significantly increased from 30% (control) to 51% (treated) but was less marked than that of RVC-588. The blood flow in the eye tissues was not significantly increased by RVC-588, but there was a clear tendency to enhance in the retina, choroid and iris. These results indicate that NO can be released effectively from S-nitrosothiols but less significantly from furoxans. Topics: Animals; Electroretinography; Eye; Female; Glutathione; Nitric Oxide; Nitroso Compounds; Ocular Hypertension; Oxadiazoles; Rabbits; Rats; Retina; Retinal Artery; S-Nitrosoglutathione; Vasodilator Agents | 1997 |